CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.
|Articles|November 1, 1997
The American Journal of Managed Care
- November 1997
- Volume 3
- Issue 11
Healthcare Utilization Among Women with Eating Disordered Behavior
Advertisement
Articles in this issue
almost 29 years ago
Empiric Examination of Physician Behavior in a Changing Healthcare Marketalmost 29 years ago
Postpartum Depressionalmost 29 years ago
Pharmaceutical Considerations of Common Herbal Medicinealmost 29 years ago
When Is a Cost-Effectiveness Claim Valid? How Much Should the FDA Care?almost 29 years ago
Treatment Patterns for Heart Failure in a Primary Care Environmentalmost 29 years ago
Enhancement of Compliance Among Patients with HypertensionAdvertisement
Related to this article
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
Advertisement
Advertisement
Trending on AJMC
1
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
2
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
3
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
4
Dialysis Access, Church CKD Screening Address Kidney Care Inequities
5